Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $36.00 at Wedbush

Stoke Therapeutics (NASDAQ:STOK) had its target price boosted by equities research analysts at Wedbush from $32.00 to $36.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price target suggests a potential upside of 9.59% from the stock’s current price.

A number of other research firms have also weighed in on STOK. UBS Group set a $50.00 target price on shares of Stoke Therapeutics in a research note on Monday, December 15th. JPMorgan Chase & Co. lifted their price objective on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a research report on Monday, November 3rd. BTIG Research reissued a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 5th. HC Wainwright raised their target price on Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, Loop Capital set a $35.00 price target on Stoke Therapeutics in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Stoke Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.10.

Stoke Therapeutics Stock Down 2.5%

Shares of STOK opened at $32.85 on Monday. Stoke Therapeutics has a 52-week low of $5.35 and a 52-week high of $38.69. The stock has a market cap of $1.88 billion, a PE ratio of 49.03 and a beta of 1.10. The firm’s fifty day moving average is $30.17 and its two-hundred day moving average is $23.82.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). The business had revenue of $10.63 million during the quarter, compared to analyst estimates of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. As a group, research analysts anticipate that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Insider Activity at Stoke Therapeutics

In other news, insider Barry Ticho sold 5,931 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $25.72, for a total value of $152,545.32. Following the transaction, the insider directly owned 7,195 shares in the company, valued at approximately $185,055.40. This represents a 45.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 13,430 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $32.27, for a total value of $433,386.10. Following the transaction, the director owned 49,124 shares of the company’s stock, valued at approximately $1,585,231.48. This represents a 21.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 104,705 shares of company stock worth $3,070,910. 9.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors have recently bought and sold shares of STOK. Generali Investments Management Co LLC acquired a new position in shares of Stoke Therapeutics during the third quarter worth $41,000. BNP Paribas Financial Markets lifted its holdings in Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after buying an additional 1,668 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares in the last quarter. Strs Ohio purchased a new position in shares of Stoke Therapeutics in the 3rd quarter valued at about $150,000. Finally, Osaic Holdings Inc. raised its position in shares of Stoke Therapeutics by 263.3% during the 2nd quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock worth $85,000 after acquiring an additional 5,427 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.